60 Degrees Pharmaceuticals (SXTP) said Tuesday it received approval from an investigational review board for a phase 2 clinical study of Arakoda, or tafenoquine, to treat patients with a presumptive diagnosis of chronic babesiosis.
The company expects patient enrollment to start in Q3. Study participants will have experienced "significant" functional impairment for at least six months, the company said.
Babesiosis is a tick-borne illness caused by Babesia parasites that develop and multiply in red blood cells.
60 Degrees shares were down 9.4% in recent trading.
Price: 0.79, Change: -0.08, Percent Change: -9.37
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.